Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59808 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL25660495 | 0.83 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL15349976 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL1065159 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL10404524 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL1065160 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL1539193 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL4854899 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL4854895 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA | |
| SCHEMBL11152703 | 0.81 | SLC7A5 (0.45) | SLC7A5CYP3A4CYP1A2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (US) | 2026-04-16 | — | — | US | claimed |
| US-20250122239-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2025-04-17 | — | — | US | claimed |
| WO-2025069009-A1 | ROCK2 INHIBITORS IN THE TREATMENT OF OBESITY | GRAVITON BIOSCIENCE BV (NL) | 2025-04-03 | — | — | WO | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| EP-3891176-B1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | HOLST BIRGITTE (DK) | 2024-06-05 | — | — | EP | claimed |
| CN-117778530-A | Method for adding preset joint to 5' end of single-stranded DNA | 清华大学 | 2024-03-29 | — | — | CN | claimed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | claimed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | claimed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | claimed |
| WO-2001098331-A2 | GLUCAGON-LIKE PEPTIDE-1 ANALOGS | ELI LILLY AND COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| US-6277819-B1 | GLUCAGON LIKE PEPTIDE1 (GLP-1) USED TO NORMALIZE BLOOD GLUCOSE IN DIABETIC PATIENTS | ELI LILLY AND COMPANY | 2001-08-21 | — | — | US | claimed |
| EP-1049486-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 2000-11-08 | — | — | EP | claimed |
| US-6133235-A | FOR TREATING MATURITY ONSET DIABETES MELLITUS IN MAMMALS, PARTICULARLY HUMANS | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | claimed |
| US-5981488-A | POLYPEPTIDE; ANTIDIABETIC AGENT | ELI LILLLY AND COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| US-5977071-A | COMPLEXES; ANTIDIABETIC AGENT | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | claimed |
| WO-1999029336-A1 | GLP-1 FORMULATIONS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | claimed |
| WO-1998043658-A1 | GLUCAGON-LIKE PEPTIDE-1 ANALOGS | ELI LILLY AND COMPANY (US) | 1998-10-08 | — | — | WO | claimed |
| EP-0869135-A1 | Glucagon-like peptide-1 analogs | ELI LILLY AND COMPANY (US) | 1998-10-07 | — | — | EP | claimed |
| EP-0733644-A1 | Glucagon-like insulinotropic complexes, compositions and methods | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103499-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | CBR1, CBR3, SIGMAR1 | SLC7A5 424/4885CYP3A4 59/4885CYP1A2 212/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | SLC7A5 66/4885CYP3A4 3633/4885CYP1A2 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.